Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Disparities in PCSK9 Initiation Among US Veterans with Peripheral Arterial Disease or Cerebrovascular Disease

Disparities in PCSK9 Initiation Among US Veterans with Peripheral Arterial Disease or... BackgroundEffective lipid lowering is essential in patients with peripheral arterial disease (PAD) and cerebrovascular disease (CeVD). Proprotein convertase subtilsin/kexin type 9 inhibitors (PCSK9i) efficiently lower low-density lipoprotein (LDL) levels; however, use in PAD and CeVD patients is limited. Therefore, our aim was to evaluate the use of PCSK9i among US Veterans and compare rates between patients with PAD, CeVD, and coronary artery disease (CAD).MethodsWe evaluated PCSK9i initiation (2016–2019) in US Veterans with CAD, PAD, or CeVD treated at 124 Veterans Affairs (VA) hospitals. We fit a hierarchical logistic regression model to evaluate the association of the patient’s primary diagnosis, baseline low-density lipoprotein cholesterol (LDL-C) levels, socioeconomic indicators, and the Department of Veterans Affairs medical center enrollment with PCSK9i initiation.ResultsOf 519,566 patients with atherosclerotic vascular disease, 337,766 (65%), 79,926 (15%) and 101,874 (20%) had CAD, PAD, and CeVD, respectively. Among 2115/519,566 (0.4%) initiated on PCSK9i therapy, 84.3% had CAD, while only 7.2% and 8.5% had PAD and CeVD, respectively. Compared with CAD patients, PAD {odds ratio [OR] 0.50 (0.36–0.70)} and CeVD [OR 0.24 (0.15–0.37)] patients were less likely to receive PCSK9i. Relative to under $40K per year, PCSK9i initiation was higher if earning $40,000–$80,000 [OR 1.13 (1.01–1.27)] or > $80,000 [OR 1.41 (1.14–1.75)]. Even moderate community deprivation [OR 0.87 (0.77–0.97)] was associated with lower PCSK9i therapy.ConclusionsAdjusted for LDL-C levels, PAD and CeVD patients are much less likely to receive PCSK9i therapy. Despite low co-pay, PCSK9i initiation rates among US veterans, nationwide, is low, with household income and community deprivation appearing to predict PCSK9i use. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cardiovascular Drugs Springer Journals

Disparities in PCSK9 Initiation Among US Veterans with Peripheral Arterial Disease or Cerebrovascular Disease

Download PDF
11 pages

Loading next page...
 
/lp/springer-journals/disparities-in-pcsk9-initiation-among-us-veterans-with-peripheral-E2HABiJOKX
Publisher
Springer Journals
Copyright
Copyright © This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2023
ISSN
1175-3277
eISSN
1179-187X
DOI
10.1007/s40256-023-00576-7
Publisher site
See Article on Publisher Site

Abstract

BackgroundEffective lipid lowering is essential in patients with peripheral arterial disease (PAD) and cerebrovascular disease (CeVD). Proprotein convertase subtilsin/kexin type 9 inhibitors (PCSK9i) efficiently lower low-density lipoprotein (LDL) levels; however, use in PAD and CeVD patients is limited. Therefore, our aim was to evaluate the use of PCSK9i among US Veterans and compare rates between patients with PAD, CeVD, and coronary artery disease (CAD).MethodsWe evaluated PCSK9i initiation (2016–2019) in US Veterans with CAD, PAD, or CeVD treated at 124 Veterans Affairs (VA) hospitals. We fit a hierarchical logistic regression model to evaluate the association of the patient’s primary diagnosis, baseline low-density lipoprotein cholesterol (LDL-C) levels, socioeconomic indicators, and the Department of Veterans Affairs medical center enrollment with PCSK9i initiation.ResultsOf 519,566 patients with atherosclerotic vascular disease, 337,766 (65%), 79,926 (15%) and 101,874 (20%) had CAD, PAD, and CeVD, respectively. Among 2115/519,566 (0.4%) initiated on PCSK9i therapy, 84.3% had CAD, while only 7.2% and 8.5% had PAD and CeVD, respectively. Compared with CAD patients, PAD {odds ratio [OR] 0.50 (0.36–0.70)} and CeVD [OR 0.24 (0.15–0.37)] patients were less likely to receive PCSK9i. Relative to under $40K per year, PCSK9i initiation was higher if earning $40,000–$80,000 [OR 1.13 (1.01–1.27)] or > $80,000 [OR 1.41 (1.14–1.75)]. Even moderate community deprivation [OR 0.87 (0.77–0.97)] was associated with lower PCSK9i therapy.ConclusionsAdjusted for LDL-C levels, PAD and CeVD patients are much less likely to receive PCSK9i therapy. Despite low co-pay, PCSK9i initiation rates among US veterans, nationwide, is low, with household income and community deprivation appearing to predict PCSK9i use.

Journal

American Journal of Cardiovascular Drugs – Springer Journals

Published: May 1, 2023

References

  • 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
    Grundy, SM; Stone, NJ; Bailey, AL; Beam, C; Birtcher, KK; Blumenthal, RS
  • The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial
    Baigent, C; Landray, MJ; Reith, C; Emberson, J; Wheeler, DC; Tomson, C
  • Ezetimibe added to statin therapy after acute coronary syndromes
    Cannon, CP; Blazing, MA; Giugliano, RP; McCagg, A; White, JA; Theroux, P
  • Add-on ezetimibe treatment to low-dose statins vs medium-intensity statin monotherapy in coronary artery disease patients with poorly controlled dyslipidemia
    Sakuma, M; Toyoda, S; Hashimoto, R; Yazawa, H; Masuyama, T; Hirose, S
  • Evolocumab and clinical outcomes in patients with cardiovascular disease
    Sabatine, MS; Giugliano, RP; Keech, AC; Honarpour, N; Wiviott, SD; Murphy, SA
  • Alirocumab and cardiovascular outcomes after acute coronary syndrome
    Schwartz, GG; Steg, PG; Szarek, M; Bhatt, DL; Bittner, VA; Diaz, R
  • PCSK9 inhibitor use in the real world: data from the national patient-centered research network
    Chamberlain, AM; Gong, Y; Shaw, KM; Bian, J; Song, WL; Linton, MF
  • Predictors of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) inhibitor prescriptions for secondary prevention of clinical atherosclerotic cardiovascular disease
    Blumenthal, DM; Maddox, TM; Aragam, K; Sacks, CA; Virani, SS; Wasfy, JH
  • Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy: Payer Approvals and Rejections, and Patient Characteristics for Successful Prescribing
    Hess, GP; Natarajan, P; Faridi, KF; Fievitz, A; Valsdottir, L; Yeh, RW
  • Factors associated with PCSK9 inhibitor initiation among US veterans
    Derington, CG; Colantonio, LD; Herrick, JS; Cook, J; King, JB; Rosenson, RS
  • Relationship of neighborhood deprivation and outcomes of a comprehensive ST-segment-elevation myocardial infarction protocol
    Huded, CP; Dalton, JE; Kumar, A; Krieger, NI; Kassis, N; Phelan, M
  • Impact of socioeconomic status on mortality and readmission in patients with heart failure with reduced ejection fraction: the ARIC Study
    Mathews, L; Ding, N; Mok, Y; Shin, JI; Crews, DC; Rosamond, WD
  • Material community deprivation and hospital utilization during the first year of life: an urban population-based cohort study
    Brokamp, C; Beck, AF; Goyal, NK; Ryan, P; Greenberg, JM; Hall, ES
  • Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research
    Austin, PC
  • Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration
    Vandenbroucke, JP; Von Elm, E; Altman, DG; Gotzsche, PC; Mulrow, CD; Pocock, SJ
  • 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
    Gerhard-Herman, MD; Gornik, HL; Barrett, C; Barshes, NR; Corriere, MA; Drachman, DE
  • Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association
    Kernan, WN; Ovbiagele, B; Black, HR; Bravata, DM; Chimowitz, MI; Ezekowitz, MD
  • Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)
    Bonaca, MP; Nault, P; Giugliano, RP; Keech, AC; Pineda, AL; Kanevsky, E
  • Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis
    Giugliano, RP; Pedersen, TR; Saver, JL; Sever, PS; Keech, AC; Bohula, EA
  • Effectiveness of blood lipid management in patients with peripheral artery disease
    Hess, CN; Cannon, CP; Beckman, JA; Goodney, PP; Patel, MR; Hiatt, WR
  • PCSK9 Inhibitors Prior Authorization
    Nasir, K; Angraal, S; Virani, SS
  • Association between copayment and adherence to statin treatment initiated after coronary heart disease hospitalization: a longitudinal, retrospective, cohort study
    Ye, X; Gross, CR; Schommer, J; Cline, R; St Peter, WL
  • Value-based insurance design in Louisiana: blue cross blue shield's zero dollar Co-pay program
    Yuan, X; Chaisson, J; Cantrell, D; Mohundro, BL; Carby, M; Ford, M
  • Navigating between Scylla and Charybdis: challenges and strategies for implementing guideline-directed medical therapy in heart failure with reduced ejection fraction
    Seferovic, PM; Polovina, M; Adlbrecht, C; Belohlavek, J; Chioncel, O; Goncalvesova, E
  • Racial and ethnic disparities in prescription coverage and medication use
    Briesacher, B; Limcangco, R; Gaskin, D
  • Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management
    Stroes, ES; Thompson, PD; Corsini, A; Vladutiu, GD; Raal, FJ; Ray, KK
  • Treatment patterns and patient characteristics among early initiators of PCSK9 inhibitors
    Hines, DM; Rane, P; Patel, J; Harrison, DJ; Wade, RL
  • Low-density lipoprotein cholesterol reduction and target achievement after switching from statin monotherapy to statin/ezetimibe combination therapy: real-world evidence
    Lee, J; Lee, SH; Kim, H; Lee, SH; Cho, JH; Lee, H